{
  "protocolSection": {
    "identificationModule": null,
    "descriptionModule": null,
    "conditionsModule": null,
    "designModule": null,
    "armsInterventionsModule": null,
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Dose-response effect of AZD5718 on urinary albumin-to-creatinine ratio (UACR)",
          "description": "Change in UACR from baseline to 20 weeks (on treatment with dapagliflozin as future standard of care). UACR is calculated as urine albumin (mg/dl) divided by urine creatinine (g/dl). The geometric mean UACR is calculated from triplicate first morning urine samples collected on 3 consecutive days before each study visit.",
          "timeFrame": "Baseline to 20 weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Dose-response effect of AZD5718 on urinary albumin-to-creatinine ratio at 12 weeks",
          "description": "Change in UACR from baseline to 12 weeks (on current standard of care without dapagliflozin)",
          "timeFrame": "Baseline to 12 weeks"
        },
        {
          "measure": "Safety and tolerability of AZD5718",
          "description": "Assessment includes monitoring of adverse events and serious adverse events, physical examinations, vital signs (blood pressure, heart rate, respiratory rate, body temperature, pulse oximetry), electrocardiography, and clinical laboratory tests (chemistry, hematology, coagulation, urinalysis)",
          "timeFrame": "Throughout the study (up to 24 weeks including follow-up)"
        },
        {
          "measure": "Effect of AZD5718 on ambulatory blood pressure",
          "description": "Change in 24-hour mean systolic blood pressure from baseline to week 12, using a noninferiority margin of 3 mm Hg",
          "timeFrame": "Baseline to 12 weeks"
        },
        {
          "measure": "Pharmacokinetics of AZD5718",
          "description": "Pre-dose plasma samples collected throughout the study to assess AZD5718 concentrations. A subgroup of at least 80 participants will provide 4 post-dose samples at 1-2, 2-5, 5-8, and 8-12 hours after receiving AZD5718 at week 4",
          "timeFrame": "Throughout the study (up to 20 weeks)"
        },
        {
          "measure": "Effect of AZD5718 on kidney function with and without dapagliflozin",
          "description": "Assessment of acute changes in estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation",
          "timeFrame": "Throughout the study (up to 20 weeks)"
        }
      ],
      "otherOutcomes": [
        {
          "measure": "Dose-response effect of AZD5718 on urinary and plasma leukotriene E4 levels",
          "description": "Inhibition of the 5-lipoxygenase pathway assessed by measuring leukotriene E4 concentrations in urine (expressed relative to creatinine concentrations) and plasma",
          "timeFrame": "Throughout the study (up to 20 weeks)"
        },
        {
          "measure": "Biomarkers that respond to treatment with AZD5718",
          "description": "Plasma, serum, and urine samples collected for analysis of biomarkers including high-sensitivity C-reactive protein, interleukin-6, and PRO-C6",
          "timeFrame": "Throughout the study (up to 20 weeks)"
        },
        {
          "measure": "Biomarkers that may predict response to treatment with AZD5718",
          "description": "Baseline sample collection for investigation of biomarkers that may predict response to treatment",
          "timeFrame": "Baseline"
        },
        {
          "measure": "Effect of AZD5718 on diabetic retinopathy in patients with diabetic kidney disease",
          "description": "Optional exploratory assessment in participants with diabetic kidney disease using ETDRS charts to test visual acuity and optical coherence tomography to measure central subfield thickness",
          "timeFrame": "Baseline and 12 weeks"
        },
        {
          "measure": "Pharmacokinetics of dapagliflozin",
          "description": "Pre-dose plasma samples collected to assess dapagliflozin concentrations after 8 weeks of treatment",
          "timeFrame": "After 8 weeks of dapagliflozin treatment (weeks 13-20)"
        }
      ]
    },
    "eligibilityModule": null
  }
}